Patients with radiological appearances consistent with diffuse glioma or tissue-proven diffuse glioma Cancer
Conditions
Interventions
Patients with radiological appearances consistent with diffuse glioma or tissue-proven diffuse glioma will undergo magnetic resonance spectroscopy scanning to assess IDH mutation status via the presen
IDH status will be compared with in vivo MRS detected 2-HG. Additional proteomic, metabolomic and gene expression tissue analysis will also be performed.
Sponsors
University of Edinburgh
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Radiological appearances consistent with diffuse glioma or tissue proven diffuse glioma 2. A signed and dated, informed consent must be obtained prior to study participation 3. Adults aged 18 - 75 years 4. WHO performance status 0 – 1 5. Measurable disease in the case of post-surgery subjects
Exclusion criteria
Exclusion criteria: 1. Participants for whom MRI is contraindicated 2. Patients with tumours in locations that preclude tissue sampling by biopsy or surgical resection. 3. Patients whose co-morbidities or functional status precludes tissue acquisition by biopsy or surgical resection.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 hydroxyglutarate concentration determined using in vivo MR spectroscopy at the time of MRI examination | — |
Secondary
| Measure | Time frame |
|---|---|
| IDH mutation status as determined by immunohistochemistry and gene sequencing from tissue samples collected at the time of surgery | — |
Countries
Scotland, United Kingdom
Outcome results
None listed